Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAOI

BTOG

CLLS

DGLY

DOCU

ICON

LGCB

OLMA

RBRK

RDUS

RNAZ

SEPN

SIBN

SNES

ULTA

XPEV

XPOF

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

Eurozone

Commodities

PRFX

PTPI

SMCI

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

BPTH

HCTI

US Stocks Mixed; NY State Business Activity Rises In February

Septerna Inc

Press Releases

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Management

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Septerna to Present at TD Cowen 45th Annual Health Care Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

Wells Fargo

Cantor Fitzgerald

JP Morgan

Comments

Septerna

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga